Fennec Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Fennec Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Fennec Pharmaceuticals Inc recorded a cumulative net loss of $-3 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -3.15%.

However, within the Healthcare sector 260 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3332, from total ROA ranking in the first quarter of 2026 at 4013.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	80.25 %	65.4 %	50.13 %	21.29 %	1.03 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-3	-8	-10	-5	-10
Return On Assets (TTM)	-3.15 %	-9.26 %	-12.34 %	-7.1 %	-15.09 %
FENC's Total Ranking	# 3332	# 4013	#	#	#
Total Assets (TTM) in million	115	116	110	71	64
Seq. Total Assets Change	-1.05 %	5.5 %	54.19 %	11.99 %	-9.21 %
Seq. Net Income Change	881.59 %	-	-	-	-

FENC's 5 Years Annual ROA >> Back to FENC Management Effectiveness >> Compare FENC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 28
Sector	# 261
Overall	# 2952

Return On Assets Statistics
High	Average	Low
229.11 %	-72.89 %	-442.57 %
(Mar 31 2014)		(Mar 31 2013)

News about Fennec Pharmaceuticals Inc Return on Assets ROA

Fennec Pharmaceuticals Appoints Industry Leader Jeffrey S. Hackman as CEO to Drive Commercial Success and Spearhead Oncology Innovations

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~
Fennec Pharmaceuticals Inc, a leading biopharmaceutical company focused on the development of innovative oncology treatments, has recently announced the appointment of Jeffrey S. Hackman as its new Chief Executive Officer (CEO) and Director. With a strong track record in the pharmaceutical industry, Hackman s extensive commercialization and oncology expertise positions him well to lead Fennec Pharmaceuticals into its next phase of growth and success.
Hackman brings over 20 years of experience in the pharmaceutical industry, with a deep understanding of drug development, regulatory affairs, and commercialization strategies. He has held various executive positions in renowned companies within the healthcare sector, including Bristol Myers Squibb, Eli Lilly, and Merck and Co. His proven leadership qualities have driven significant revenue growth and successful product launches, making him an ideal choice to guide Fennec Pharmaceuticals towards achieving its goals.

Financial Statements
Fennec Pharmaceuticals Inc 's Assets	$ 115 million	FENC's Balance sheet
Fennec Pharmaceuticals Inc 's Income	$ 2 million	Quarterly FENC's Income Statement
FENC's Income by Division		See FENC's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	50.13 %	164.7 %	1.48 %	-51.78 %	-10.05 %
Total Assets in million	110	73	28	27	57
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-10	0	-16	-24	-17
Annual Return On Assets	-8.84 %	-0.59 %	-57.86 %	-86.78 %	-30.61 %

FENC's 5 Years Annual ROA >> Back to FENC Management Effectiveness >> Compare FENC ROA to its Competitors

More Return On Assets Ratios
FENC's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
FENC's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for FENC's Competitors
Subscribers only: Roa for Fennec Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for FENC's Customers

You may also want to know
FENC's Roi	FENC's Inventory Turnover Ratio	FENC's Growth Rates	FENC's Dividend Comparisons
	FENC's Profitability Ratios	FENC's Asset Turnover Ratio	FENC's Dividend Growth
FENC's Roe	FENC's Valuation Ratios	FENC's Financial Strength Ratios	FENC's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T11:45:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.